GENE COMPANY
Live / Applied — Response to non-final action entered (as of 31 Mar 2025)
What this means for you
Not registered yet, but its 14 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79397452
- Mark type
- Design + words
- Filed
- 14 Mar 2024
- Attorney of record
- Michael T. Smith
Goods and services
- Class 001 — Chemicals: Chemical, biological, and bacteriological preparations, other than for medical or veterinary use, for scientific and research use, or for the manufacture of pharmaceuticals; chemical, biological, and bacteriological preparations for scientific and research use, or for the manufacture of pharmaceuticals, namely, preparations containing RNA nanoparticle technologies; RNA nanoparticles, namely, RNA packaged lipid nanoparticles, RNA packaged cell derived extracellular vesicles, chemically modified RNAs capable of naked delivery for scientific, laboratory or medical research use
- Class 005 — Pharmaceuticals: Diagnostic medical, biological, and pharmaceutical preparations for SARS, Flu, MRSA, Dengue, COPD, Idiopathic pulmonary fibrosis, liver failure, liver cancer, NASH, Stroke, Pancreatic cancer, oral squamous cell cancer, Acute myloid leukemia (AML), skin burn, skin scarring, skin aging, eye diseases such as vitreoretinal eye disease, and Macular degeneration, diabetes, obesity for medical laboratory use; vaccines; vaccine adjuvants; DIAGNOSTIC medical, biological, and pharmaceutical preparations for SARS, Flu, MRSA, Dengue, COPD, Idiopathic pulmonary fibrosis, liver failure, liver cancer, NASH, Stroke, Pancreatic cancer, oral squamous cell cancer, Acute myloid leukemia (AML), skin burn, skin scarring, skin aging, eye diseases such as vitreoretinal eye disease, and Macular degeneration, diabetes, obesity for medical use, namely, preparations containing novel RNA nanoparticle technologies; nanoparticle formulations for pharmaceutical, medical or medical diagnostic purposes, namely, RNA packaged lipid and extravesicular nanoparticles; backbone modified conjugated RNAs, drug delivery agents for medical use consisting of RNA nanoparticle formulations that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations comprising drug delivery agents based on RNA nanoparticle formulations; pharmaceutical preparations, namely, RNA and delivery agents comprised of nanoparticle carriers and polymers for the delivery of RNA to human cells
- Class 040 — Treatment of materials: Custom manufacture of pharmaceutical products including manufacture of pharmaceutical preparations containing RNA, nucleic acids, protein nanoparticles; providing information in the field of custom manufacture of pharmaceuticals
- Class 042 — Scientific and technological services: Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology, namely, design and testing for new product development; design, engineering, research, and development services in the field of novel RNA nanoparticle technologies for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines
Owner
Prosecution history
- 30 Nov 2025 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 12 Nov 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 12 Nov 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 31 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 31 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 31 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Oct 2024 — REFUSAL PROCESSED BY IB
- 30 Sept 2024 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 30 Sept 2024 — REFUSAL PROCESSED BY MPU
- 26 Sept 2024 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 25 Sept 2024 — NON-FINAL ACTION WRITTEN
- 24 Sept 2024 — ASSIGNED TO EXAMINER
- 20 Jun 2024 — APPLICATION FILING RECEIPT MAILED
- 20 Jun 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 13 Jun 2024 — SN ASSIGNED FOR SECT 66A APPL FROM IB